Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R. Bourgeois S, et al. Among authors: van vlierberghe h, van remoortere p. BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2. BMC Gastroenterol. 2017. PMID: 28187751 Free PMC article. Clinical Trial.
Hepatitis C virus: the burden of the disease.
Adler M, Goubau P, Nevens F, Van Vlierberghe H. Adler M, et al. Among authors: van vlierberghe h. Acta Gastroenterol Belg. 2002 Apr-Jun;65(2):83-6. Acta Gastroenterol Belg. 2002. PMID: 12148444 Review.
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Van Vlierberghe H, et al. J Viral Hepat. 2003 Nov;10(6):460-6. doi: 10.1046/j.1365-2893.2003.00466.x. J Viral Hepat. 2003. PMID: 14633181 Clinical Trial.
Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L; Belgian Assocation for the Study of the Liver. Horsmans Y, et al. Among authors: van vlierberghe h. Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):293-7. Acta Gastroenterol Belg. 2008. PMID: 19198574 Clinical Trial.
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F. Langlet P, et al. Among authors: van vlierberghe h. Aliment Pharmacol Ther. 2009 Aug 15;30(4):352-63. doi: 10.1111/j.1365-2036.2009.04052.x. Epub 2009 May 26. Aliment Pharmacol Ther. 2009. PMID: 19485978 Free article. Clinical Trial.
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study.
Van Vlierberghe H, Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay JP, Van Steenbergen W, Yap P, Nevens F, Denys AM, Brasseur JP. Van Vlierberghe H, et al. Among authors: van steenbergen w. Acta Gastroenterol Belg. 2010 Jan-Mar;73(1):5-11. Acta Gastroenterol Belg. 2010. PMID: 20458844 Free article.
A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients.
Nevens F, Van Vlierberghe H, D'Heygere E, Delwaide J, Adler M, Henrion J, Lenaerts A, Hendlisz A, Michielsen P, Bastens B, Brenard R, Laureys A; BERNAR-1 Study Group. Nevens F, et al. Among authors: van vlierberghe h. Acta Gastroenterol Belg. 2010 Apr-Jun;73(2):223-8. Acta Gastroenterol Belg. 2010. PMID: 20690560 Free article. Clinical Trial.
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group. Orlent H, et al. Among authors: van vlierberghe h. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3. Eur J Gastroenterol Hepatol. 2010. PMID: 21389795 Clinical Trial.
335 results